NO985622D0 - Utvalgte derivater av K-252A - Google Patents

Utvalgte derivater av K-252A

Info

Publication number
NO985622D0
NO985622D0 NO985622A NO985622A NO985622D0 NO 985622 D0 NO985622 D0 NO 985622D0 NO 985622 A NO985622 A NO 985622A NO 985622 A NO985622 A NO 985622A NO 985622 D0 NO985622 D0 NO 985622D0
Authority
NO
Norway
Prior art keywords
selected derivatives
survival
enhancing
compounds
represented
Prior art date
Application number
NO985622A
Other languages
English (en)
Other versions
NO985622L (no
NO312464B1 (no
Inventor
Robert L Hudkins
John P Mallamo
Masami Hamano
Reiko Tanaka
Chikara Murakata
Original Assignee
Cephalon Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc, Kyowa Hakko Kogyo Kk filed Critical Cephalon Inc
Publication of NO985622D0 publication Critical patent/NO985622D0/no
Publication of NO985622L publication Critical patent/NO985622L/no
Publication of NO312464B1 publication Critical patent/NO312464B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NO19985622A 1996-06-03 1998-12-02 Utvalgte derivater av K-252a og anvendelse derav NO312464B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65736696A 1996-06-03 1996-06-03
PCT/US1997/009448 WO1997046565A1 (en) 1996-06-03 1997-06-02 SELECTED DERIVATIVES OF K-252a

Publications (3)

Publication Number Publication Date
NO985622D0 true NO985622D0 (no) 1998-12-02
NO985622L NO985622L (no) 1999-02-02
NO312464B1 NO312464B1 (no) 2002-05-13

Family

ID=24636859

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19985622A NO312464B1 (no) 1996-06-03 1998-12-02 Utvalgte derivater av K-252a og anvendelse derav

Country Status (18)

Country Link
US (1) US6306849B1 (no)
EP (1) EP0918777B1 (no)
JP (1) JP2000511902A (no)
CN (1) CN1198827C (no)
AT (1) ATE222912T1 (no)
AU (1) AU716656B2 (no)
BR (1) BR9711093A (no)
CA (1) CA2256633C (no)
DE (1) DE69715010T2 (no)
DK (1) DK0918777T3 (no)
ES (1) ES2183184T3 (no)
HK (1) HK1018703A1 (no)
NO (1) NO312464B1 (no)
NZ (2) NZ333018A (no)
PT (1) PT918777E (no)
RU (1) RU2205184C2 (no)
UA (1) UA67725C2 (no)
WO (1) WO1997046565A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP1126855B1 (en) 1998-09-25 2007-05-09 Cephalon, Inc. Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
WO2004016167A1 (en) * 2002-08-16 2004-02-26 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
CA2500901A1 (en) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003304238A1 (en) * 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
MXPA05003502A (es) * 2002-10-08 2005-09-30 Rinat Neuroscience Corp Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo.
NZ540730A (en) * 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
ATE491444T1 (de) * 2003-02-19 2011-01-15 Rinat Neuroscience Corp Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
KR101504729B1 (ko) 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
DK2381964T3 (da) * 2008-12-22 2014-09-29 Creabilis S A Syntese af polymerkonjugater af indolocarbazolforbindelser

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554402A (en) 1983-12-23 1985-11-19 Aluminum Company Of America Vibration damper for overhead conductor
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
WO1988007045A1 (en) 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
JP2766360B2 (ja) 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
DE3835842A1 (de) 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
AU7035991A (en) 1989-12-14 1991-07-18 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
JPH0586068A (ja) 1991-03-04 1993-04-06 Rikagaku Kenkyusho 新規抗生物質ｒｋ−１４０９、その製造法並びに抗腫瘍剤及び抗炎症剤
CA2123096A1 (en) 1991-11-08 1993-05-13 Beat J. Knusel Compositions containing k-252 compounds for potentiation of neurotrophin activity
JP2593021B2 (ja) 1991-12-13 1997-03-19 伊藤ハム株式会社 ウシ胚の性の識別方法
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
DE69326388T2 (de) 1992-06-22 1999-12-30 Kyowa Hakko Kogyo Kk Verfahren zur Herstellung von Staurosporin-Derivaten
JPH0673063A (ja) 1992-06-22 1994-03-15 Kyowa Hakko Kogyo Co Ltd Ｕｃｎ−０１誘導体
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE69331228D1 (en) * 1992-09-21 2002-01-10 Kyowa Hakko Kogyo Kk Heilmittel für thrombozytopenia
ES2118414T3 (es) 1993-05-28 1998-09-16 Cephalon Inc Utilizacion de derivados del indolocarbazol para el tratamiento de la prostata.
EP0703917A1 (en) 1993-06-17 1996-04-03 Novartis AG Indolocarbazole compound useful as proteinkinase c inhibitor
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

Also Published As

Publication number Publication date
CN1198827C (zh) 2005-04-27
AU716656B2 (en) 2000-03-02
WO1997046565A1 (en) 1997-12-11
CA2256633A1 (en) 1997-12-11
CN1226893A (zh) 1999-08-25
ATE222912T1 (de) 2002-09-15
AU3225397A (en) 1998-01-05
RU2205184C2 (ru) 2003-05-27
NZ333018A (en) 2000-05-26
NO985622L (no) 1999-02-02
DE69715010T2 (de) 2003-04-03
PT918777E (pt) 2003-01-31
NO312464B1 (no) 2002-05-13
EP0918777A1 (en) 1999-06-02
HK1018703A1 (en) 1999-12-30
JP2000511902A (ja) 2000-09-12
CA2256633C (en) 2009-04-07
NZ504097A (en) 2005-06-24
DE69715010D1 (de) 2002-10-02
UA67725C2 (en) 2004-07-15
ES2183184T3 (es) 2003-03-16
EP0918777B1 (en) 2002-08-28
BR9711093A (pt) 1999-08-17
US6306849B1 (en) 2001-10-23
DK0918777T3 (da) 2002-12-30

Similar Documents

Publication Publication Date Title
NO985622D0 (no) Utvalgte derivater av K-252A
EP0630898A4 (en) MEDICINE FOR THROMBOZYTOPENIA.
MX9702682A (es) Pirrolocarbazoles fusionados.
BR9714377B1 (pt) compostos derivados de 3-tiocarbamoilpirazol, seus processos de preparaÇço, uso, assim como pesticidas contendo referidos compostos.
ES8400438A1 (es) Procedimiento para preparar derivados de (3h)-imidazo(5,1-d)-1,2,3,5-tetrazin-4-ona.
ATE289810T1 (de) Ecteinascidinderivate
WO1994019343A3 (en) Novel use as anti-inflammatory agents for bis-heterocyclic compounds and pharmaceutical compositions thereof
IE780922L (en) 1,3,5-s-HEXAHYDROSUBSTITUTED TRIAZINES
WO1998018466A3 (en) Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
DE69812177D1 (de) 3'-epi k-252a derivate
AU578489B2 (en) Proline derivatives
DE69703115D1 (de) Zwischenprodukte um 2-imidazolin-5onederivate herzustellen.
CA2187849A1 (en) Uck14 compounds
IL86665A0 (en) Mitomycin analogs
GB9911556D0 (en) Immunosuppressant tricyclic compounds
DK0566557T3 (da) 2- og 3-amino- og azidoderivater af 1,5- iminosukkere som antivirale forbindelser
CA2272136A1 (en) Pyrazole derivatives having crf antagonist activity

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees